Fig. 4From: Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER studyEffect of treatments on surfactant protein D (SP-D) – geometric least squares mean ratio versus placebo (ITT population). *p < 0.05 vs placebo. ITT, intention-to-treat; BID, twice dailyBack to article page